Fusion Antibodies PLC Director/PDMR Shareholding (8926B)
September 25 2018 - 8:23AM
UK Regulatory
TIDMFAB
RNS Number : 8926B
Fusion Antibodies PLC
25 September 2018
Fusion Antibodies plc
("Fusion" or the "Company")
25 September 2018
Director/PDMR Shareholding
Fusion Antibodies plc (AIM: FAB), a contract research
organisation providing a range of antibody engineering services for
the development of antibodies for both therapeutic drug and
diagnostic applications, announces that it has been informed by
Alan Mawson, a Non-Executive Director of the Company, that on 24
September 2018 he purchased 8,500 ordinary shares in the Company
("Ordinary Shares") at a price of 67 pence per Ordinary Share via
his personal pension scheme. Following this purchase, Mr Mawson has
a direct beneficial interest in 38,988 Ordinary Shares, equivalent
to 0.18% of the Company's issued share capital. Alan Mawson is also
a non-executive director of Clarendon Fund Managers Limited
("Clarendon") and sits on Clarendon's investment committee.
Clarendon is the fund manager for Nitech Growth Fund LP which holds
358,850 Ordinary Shares and Viridian Growth Fund LP which holds
1,831,500 Ordinary Shares.
In addition, the Company has been informed that today Richard
Buick, Chief Technical Officer of the Company has purchased 3,000
Ordinary Shares at a price of 70.42 pence per Ordinary Share.
Following this purchase, Richard Buick holds 515,125 Ordinary
Shares in the Company, representing approximately 2.33 per cent. of
the Company's issued share capital.
The Company has also been informed that today Sonya Ferguson,
Non-Executive Director of the Company has purchased 15,307 Ordinary
Shares at a price of 65 pence per Ordinary Share. Following this
purchase, Sonya Ferguson holds 30,900 Ordinary Shares in the
Company, representing approximately 0.14 per cent. of the Company's
issued share capital.
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Dr Alan Mawson
-------------------------- ---------------------------------------
2 Reason for the notification
-------------------------------------------------------------------
a) Position/status Non-Executive Director
-------------------------- ---------------------------------------
b) Initial notification Initial notification
/Amendment
-------------------------- ---------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------
a) Name Fusion Antibodies PLC
-------------------------- ---------------------------------------
b) LEI 213800KBAYRC9VOQ9V39
-------------------------- ---------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------
a) Description of the Ordinary shares of 4p each in Fusion
financial instrument, Antibodies PLC
type of instrument
Identification code
Identification code (ISIN) for Fusion
Antibodies PLC ordinary shares:
GB00BDQZGK16
-------------------------- ---------------------------------------
b) Nature of the transaction Purchase of shares
-------------------------- ---------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
67p 8,500
----------
-------------------------- ---------------------------------------
d) Aggregated information
- Aggregated volume n/a
- Price
-------------------------- ---------------------------------------
e) Date of the transaction 24 September 2018
-------------------------- ---------------------------------------
f) Place of the transaction London Stock Exchange, XLON
-------------------------- ---------------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Dr Richard John Buick
-------------------------- ---------------------------------------
2 Reason for the notification
-------------------------------------------------------------------
a) Position/status Chief Technical Officer
-------------------------- ---------------------------------------
b) Initial notification Initial notification
/Amendment
-------------------------- ---------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------
a) Name Fusion Antibodies PLC
-------------------------- ---------------------------------------
b) LEI 213800KBAYRC9VOQ9V39
-------------------------- ---------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------
a) Description of the Ordinary shares of 4p each in Fusion
financial instrument, Antibodies PLC
type of instrument Identification code (ISIN) for Fusion
Identification code Antibodies PLC ordinary shares:
GB00BDQZGK16
-------------------------- ---------------------------------------
b) Nature of the transaction Purchase of shares
-------------------------- ---------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
70.42p 3,000
----------
-------------------------- ---------------------------------------
d) Aggregated information n/a
- Aggregated volume
- Price
-------------------------- ---------------------------------------
e) Date of the transaction 25 September 2018
-------------------------- ---------------------------------------
f) Place of the transaction London Stock Exchange, XLON
-------------------------- ---------------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Sonya Maria Ferguson
-------------------------- ---------------------------------------
2 Reason for the notification
-------------------------------------------------------------------
a) Position/status Non-Executive Director
-------------------------- ---------------------------------------
b) Initial notification Initial notification
/Amendment
-------------------------- ---------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------
a) Name Fusion Antibodies PLC
-------------------------- ---------------------------------------
b) LEI 213800KBAYRC9VOQ9V39
-------------------------- ---------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------
a) Description of the Ordinary shares of 4p each in Fusion
financial instrument, Antibodies PLC
type of instrument Identification code (ISIN) for Fusion
Identification code Antibodies PLC ordinary shares:
GB00BDQZGK16
-------------------------- ---------------------------------------
b) Nature of the transaction Purchase of shares
-------------------------- ---------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
65p 15,307
----------
-------------------------- ---------------------------------------
d) Aggregated information n/a
- Aggregated volume
- Price
-------------------------- ---------------------------------------
e) Date of the transaction 25 September 2018
-------------------------- ---------------------------------------
f) Place of the transaction London Stock Exchange, XLON
-------------------------- ---------------------------------------
Enquiries:
Fusion Antibodies plc www.fusionantibodies.com
Dr Paul Kerr, Chief Executive Officer Via Walbrook PR
James Fair, Chief Financial Officer
Allenby Capital Limited Tel: +44 (0)20 3328 5656
Virginia Bull / James Reeve / Asha Chotai
Walbrook PR Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com
Paul McManus Mob: +44 (0)7980 541 893
Anna Dunphy Mob: +44 (0)7876 741 001
About Fusion Antibodies plc
Fusion is a Belfast based contract research organisation ("CRO")
providing a range of antibody engineering services for the
development of antibodies for both therapeutic drug and diagnostic
applications.
The Company's ordinary shares were admitted to trading on AIM on
18 December 2017. Fusion provides a broad range of services in
antibody generation, development, production, characterisation and
optimisation. These services include antigen expression, antibody
production, purification and sequencing, antibody humanisation
using Fusion's proprietary CDRx(TM) platform and the production of
antibody generating stable cell lines to provide material for use
in clinical trials. Since 2012, the Company has successfully
sequenced over 250 antibodies and successfully completed over 100
humanisation projects for its international, blue-chip client base,
which includes eight of the top 10 global pharmaceutical companies
by revenue.
The Company was established in 2001 as a spin out from Queen's
University Belfast. It was initially a drug development business
but revised its operations to focus on CRO work in 2011. The
Company has a highly experienced management team with a combined 47
years' experience in the biopharma industry.
The global monoclonal antibody therapeutics market, which
accounted for 43 per cent. of the global biologics market in 2016,
was valued at between $85.4 billion and $86.7 billion in 2015 and
is forecast to increase at a CAGR of between 8.2 per cent. and 12.2
per cent. for the period 2016 to 2024.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHSEFFDIFASEEU
(END) Dow Jones Newswires
September 25, 2018 09:23 ET (13:23 GMT)
Fusion Antibodies (LSE:FAB)
Historical Stock Chart
From Apr 2024 to May 2024
Fusion Antibodies (LSE:FAB)
Historical Stock Chart
From May 2023 to May 2024